PFIZER - Pfizer Ltd. Share Price

Pharmaceuticals & Biotechnology

Sharesguru Stock Score

PFIZER

45/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

₹4706.00-78.90(-1.65%)

Market Closed as of Apr 24, 2026, 15:30 IST

Select time range

Pros

Smart Money: Smart money has been increasing their position in the stock.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Balance Sheet: Strong Balance Sheet.

Dividend: Pays a strong dividend yield of 4.36%.

Size: Market Cap wise it is among the top 20% companies of india.

Profitability: Very strong Profitability. One year profit margin are 32%.

Cons

Past Returns: In past three years, the stock has provided 8.2% return compared to 10.9% by NIFTY 50.

Momentum: Stock has a weak negative price momentum.

Technicals: SharesGuru indicator is Bearish.

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

PFIZER - Pfizer Ltd. Share Price

Pharmaceuticals & Biotechnology

Sharesguru Stock Score

PFIZER

45/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

₹4706.00-78.90(-1.65%)

Market Closed as of Apr 24, 2026, 15:30 IST

Select time range

Pros

Smart Money: Smart money has been increasing their position in the stock.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Balance Sheet: Strong Balance Sheet.

Dividend: Pays a strong dividend yield of 4.36%.

Size: Market Cap wise it is among the top 20% companies of india.

Profitability: Very strong Profitability. One year profit margin are 32%.

Cons

Past Returns: In past three years, the stock has provided 8.2% return compared to 10.9% by NIFTY 50.

Momentum: Stock has a weak negative price momentum.

Technicals: SharesGuru indicator is Bearish.

Valuation
Market Cap	21.89 kCr
Price/Earnings (Trailing)	25.64
Price/Sales (Trailing)	8.19
EV/EBITDA	18.21
Price/Free Cashflow	38.42
MarketCap/EBT	19.33
Enterprise Value	21.89 kCr

Fundamentals
Revenue (TTM)	2.67 kCr
Rev. Growth (Yr)	17.6%
Earnings (TTM)	853.55 Cr
Earnings Growth (Yr)	11.2%

Profitability
Operating Margin	38%
EBT Margin	42%
Return on Equity	22.18%
Return on Assets	18.53%
Free Cashflow Yield	2.6%

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns
Price Change 1W	-1.5%
Price Change 1M	2.6%
Price Change 6M	-10.4%
Price Change 1Y	12.8%
3Y Cumulative Return	8.2%
5Y Cumulative Return	-1.6%
7Y Cumulative Return	6.3%
10Y Cumulative Return	10.5%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-71.34 Cr
Cash Flow from Operations (TTM)	659.75 Cr
Cash Flow from Financing (TTM)	-205.34 Cr
Cash & Equivalents	205.35 Cr
Free Cash Flow (TTM)	631.6 Cr
Free Cash Flow/Share (TTM)	138.06

Balance Sheet
Total Assets	4.61 kCr
Total Liabilities	757.23 Cr
Shareholder Equity	3.85 kCr
Current Assets	3.48 kCr
Current Liabilities	645.65 Cr
Net PPE	154.63 Cr
Inventory	500.47 Cr
Goodwill	527.49 Cr

Capital Structure & Leverage
Debt Ratio	0.00
Debt/Equity	0.00
Interest Coverage	111.59
Interest/Cashflow Ops	70.08

Dividend & Shareholder Returns
Dividend/Share (TTM)	200
Dividend Yield	4.36%
Shares Dilution (1Y)	0.00%
Shares Dilution (3Y)	0.00%

Sharesguru Stock Score

PFIZER

45/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

Pros

Smart Money: Smart money has been increasing their position in the stock.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Balance Sheet: Strong Balance Sheet.

Dividend: Pays a strong dividend yield of 4.36%.

Size: Market Cap wise it is among the top 20% companies of india.

Profitability: Very strong Profitability. One year profit margin are 32%.

Cons

Past Returns: In past three years, the stock has provided 8.2% return compared to 10.9% by NIFTY 50.

Momentum: Stock has a weak negative price momentum.

Technicals: SharesGuru indicator is Bearish.

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Investor Care
Dividend Yield	4.36%
Dividend/Share (TTM)	200
Shares Dilution (1Y)	0.00%
Earnings/Share (TTM)	186.59

Financial Health
Current Ratio	5.38
Debt/Equity	0.00

Technical Indicators
RSI (14d)	45.85
RSI (5d)	38.35
RSI (21d)	48.71
MACD Signal	Buy
Stochastic Oscillator Signal	Hold
SharesGuru Signal	Sell
RSI Signal	Hold
RSI5 Signal	Hold
RSI21 Signal	Hold
SMA 5 Signal	Sell
SMA 10 Signal	Sell
SMA 20 Signal	Sell
SMA 50 Signal	Sell
SMA 100 Signal	Sell

Earnings Outlook

Q&A Session

Share Holdings

Understand Pfizer ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

Shareholder Name	Holding %
PFIZER EAST INDIA B V	39.75%
WYETH LLC	12.28%
NIPPON LIFE INDIA TRUSTEE LIMITED	4.16%
LIFE INSURANCE CORPORATION OF INDIA	3.85%
WYETH HOLDINGS CORPORATION	3.56%
WARNER-LAMBERT COMPANY LLC	2.6%
QUANT MUTUAL FUND	2.22%
ICICI PRUDENTIAL FUND	2.16%
ATUL LIMITED	2.1%
PARKE, DAVIS & COMPANY LLC	2.09%
JOHN WYETH & BROTHER LTD	1.93%
PHARMACIA CORPORATION	1.71%
FOREIGN INSTITUTIONAL INVESTORS	0%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr

Category	PFIZER	Pharmaceuticals
PE	25.64	34.88
PS	8.19	4.81
Growth	9.6 %	8 %

Key Insights

1. PFIZER is NOT among the Top 10 largest companies in Pharmaceuticals.
2. The company holds a market share of 0.6% in Pharmaceuticals.
3. The company is growing at an average growth rate of other Pharmaceuticals companies.

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	4%	2,281	2,193	2,425	2,611	2,239	2,152
Other Income	-5%	172	181	101	63	81	184
Total Income	3.4%	2,454	2,374	2,526	2,674	2,320	2,336
Cost of Materials	-19.1%	272	336	345	354	335	345
Purchases of stock-in-trade	9.4%	513	469	472	667	449	484
Employee Expense	6.6%	371	348	332	404	361	365
Finance costs	-47.1%	8.41	15	13	10	15	11
Depreciation and Amortization	-1.6%	61	62	106	115	109	103
Other expenses	-14.1%	359	418	411	424	368	422
Total Expenses	-1.6%	1,610	1,636	1,735	1,901	1,651	1,693
Profit Before exceptional items and Tax	14.2%	843	738	791	773	669	642
Exceptional items before tax	2374.8%	173	7.95	33	0	0	0
Total profit before tax	36.2%	1,016	746	824	773	669	642
Current tax	66.5%	264	159	252	218	184	133
Deferred tax	-147.5%	-15.61	36	-51.74	-58	-12.52	0.16
Total tax	27.3%	248	195	200	160	171	133
Total profit (loss) for period	39.5%	768	551	624	613	498	509
Other comp. income net of taxes	-105.8%	0.74	5.45	3.61	7.17	-0.96	-8.93
Total Comprehensive Income	37.9%	768	557	628	620	497	500
Earnings Per Share, Basic	39.6%	167.79	120.51	136.38	133.89	108.77	111.28
Earnings Per Share, Diluted	39.6%	167.79	120.51	136.38	133.89	108.77	111.28

Description	(%) Q/Q	Dec-2025	Jun-2025	Dec-2024	Sep-2024	Jun-2024	Mar-2024
Revenue From Operations	7%	645	603	538	589	563	547
Other Income	-43.9%	38	67	43	43	42	75
Total Income	1.9%	683	670	581	632	605	622
Cost of Materials	-23.9%	68	89	67	77	58	89
Purchases of stock-in-trade	17.1%	145	124	105	81	188	94
Employee Expense	4.2%	100	96	96	101	91	75
Finance costs	-56%	1.99	3.25	1.51	2.1	2.11	6.95
Depreciation and Amortization	0%	14	14	15	15	15	14
Other expenses	7.1%	92	86	99	88	93	93
Total Expenses	5.4%	433	411	408	416	402	378
Profit Before exceptional items and Tax	-3.9%	250	260	172	215	203	244
Exceptional items before tax	-	-58.2	0	0	0	0	0
Total profit before tax	-26.3%	192	260	172	215	203	244
Current tax	-13.6%	58	67	50	60	55	49
Deferred tax	-1357.4%	-7.89	0.39	-5.26	-3.01	-3.14	16
Total tax	-26.9%	50	68	45	57	52	65
Total profit (loss) for period	-26.2%	142	192	128	158	151	179
Other comp. income net of taxes	145.3%	1.87	-0.92	-0.54	-0.53	-0.54	7.93
Total Comprehensive Income	-24.7%	144	191	127	158	150	187
Earnings Per Share, Basic	-26.6%	31.01	41.91	27.89	34.61	32.94	22.33
Earnings Per Share, Diluted	-26.6%	31.01	41.91	27.89	0	32.94	22.33

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	-58.7%	205	495	35	112	16	37
Loans, current	-	0	0	0	0	0	0
Total current financial assets	-1.6%	2,950	2,998	2,531	2,247	2,082	2,076
Inventories	5.1%	500	476	455	434	399	418
Total current assets	-1%	3,477	3,513	3,023	2,738	2,518	2,493
Property, plant and equipment	-9.9%	155	172	132	151	164	178
Capital work-in-progress	-2.1%	7.5	7.64	2.82	0.4	9.38	7.93
Investment property	-	0	0	0	0	0	0
Goodwill	0%	527	527	527	527	527	527
Loans, non-current	-	0	0	0	0	0	0
Total non-current financial assets	0%	14	14	12	14	13	13
Total non-current assets	-19.3%	1,129	1,398	1,404	1,459	1,457	1,476
Total assets	-6.2%	4,606	4,911	4,459	4,229	4,006	4,001
Total non-current financial liabilities	-31.3%	47	68	38	0	73	93
Provisions, non-current	14.3%	65	57	65	0	46	43
Total non-current liabilities	-9.8%	112	124	103	87	119	136
Borrowings, current	0%	2.5	2.5	2.5	2.5	2.5	2.5
Total current financial liabilities	36.8%	317	232	281	206	323	322
Provisions, current	-10%	46	51	57	45	93	101
Current tax liabilities	16.4%	257	221	182	160	164	161
Total current liabilities	13.4%	646	570	605	547	614	657
Total liabilities	9.1%	757	694	708	633	733	793
Equity share capital	0%	46	46	46	46	46	46
Total equity	-8.8%	3,848	4,217	3,751	3,596	3,273	3,207
Total equity and liabilities	-6.2%	4,606	4,911	4,459	4,229	4,006	4,001

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	-47.1%	8.41	15	0	10	-	-
Change in inventories	-154.2%	-42.22	-16	22	-13.86	-	-
Depreciation	-1.6%	61	62	106	115	-	-
Unrealised forex losses/gains	40.2%	0.21	-0.32	0	0	-	-
Adjustments for interest income	-100.6%	0	172	85	49	-	-
Share-based payments	0%	14	14	13	12	-	-
Net Cashflows from Operations	137.1%	973	411	854	893	-	-
Interest received	-	-157.27	0	0	0	-	-
Income taxes paid (refund)	1.3%	156	154	303	226	-	-
Other inflows (outflows) of cash	-	0	0	-195.31	0	-	-
Net Cashflows From Operating Activities	157.4%	660	257	356	667	-	-
Proceeds from sales of PPE	18.4%	0.2	0.02	1.22	2.06	-	-
Purchase of property, plant and equipment	50%	28	19	65	15	-	-
Proceeds from sales of long-term assets	190.4%	152	53	0	0	-	-
Interest received	7.8%	139	129	71	44	-	-
Other inflows (outflows) of cash	-204.7%	-334.43	-109.1	-43.4	-605.54	-	-
Net Cashflows From Investing Activities	-236.5%	-71.34	54	-36.05	-575.02	-	-
Payments of lease liabilities	10%	45	41	35	0	-	-
Dividends paid	-12.6%	160	183	297	160	-	-
Interest paid	-107%	0.3	11	13	0.78	-	-
Other inflows (outflows) of cash	-	0	0	-0.63	-19.99	-	-
Net Cashflows from Financing Activities	12.6%	-205.34	-235.14	-345.79	-180.51	-	-
Net change in cash and cash eq.	416.2%	383	75	-26.14	-88.45	-	-

Pfizer Limited engages in manufacturing, marketing, trading, and export of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastro intestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers internal medicine and anti-infectives services to hospitals and nursing homes. It serves healthcare providers, government and private hospitals, and retail pharmacies. The company sells its products through a network of independent distributors. Pfizer Limited was incorporated in 1950 and is based in Mumbai, India.

Industry Group:Pharmaceuticals & Biotechnology

Employees:1,721

Website:www.pfizerltd.co.in

Important Disclosure & Data Context

This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.

Earnings Outlook

Q&A Session

Share Holdings

Understand Pfizer ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

Shareholder Name	Holding %
PFIZER EAST INDIA B V	39.75%
WYETH LLC	12.28%
NIPPON LIFE INDIA TRUSTEE LIMITED	4.16%
LIFE INSURANCE CORPORATION OF INDIA	3.85%
WYETH HOLDINGS CORPORATION	3.56%
WARNER-LAMBERT COMPANY LLC	2.6%
QUANT MUTUAL FUND	2.22%
ICICI PRUDENTIAL FUND	2.16%
ATUL LIMITED	2.1%
PARKE, DAVIS & COMPANY LLC	2.09%
JOHN WYETH & BROTHER LTD	1.93%
PHARMACIA CORPORATION	1.71%
FOREIGN INSTITUTIONAL INVESTORS	0%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr

Category	PFIZER	Pharmaceuticals
PE	25.64	34.88
PS	8.19	4.81
Growth	9.6 %	8 %

Key Insights

1. PFIZER is NOT among the Top 10 largest companies in Pharmaceuticals.
2. The company holds a market share of 0.6% in Pharmaceuticals.
3. The company is growing at an average growth rate of other Pharmaceuticals companies.

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	4%	2,281	2,193	2,425	2,611	2,239	2,152
Other Income	-5%	172	181	101	63	81	184
Total Income	3.4%	2,454	2,374	2,526	2,674	2,320	2,336
Cost of Materials	-19.1%	272	336	345	354	335	345
Purchases of stock-in-trade	9.4%	513	469	472	667	449	484
Employee Expense	6.6%	371	348	332	404	361	365
Finance costs	-47.1%	8.41	15	13	10	15	11
Depreciation and Amortization	-1.6%	61	62	106	115	109	103
Other expenses	-14.1%	359	418	411	424	368	422
Total Expenses	-1.6%	1,610	1,636	1,735	1,901	1,651	1,693
Profit Before exceptional items and Tax	14.2%	843	738	791	773	669	642
Exceptional items before tax	2374.8%	173	7.95	33	0	0	0
Total profit before tax	36.2%	1,016	746	824	773	669	642
Current tax	66.5%	264	159	252	218	184	133
Deferred tax	-147.5%	-15.61	36	-51.74	-58	-12.52	0.16
Total tax	27.3%	248	195	200	160	171	133
Total profit (loss) for period	39.5%	768	551	624	613	498	509
Other comp. income net of taxes	-105.8%	0.74	5.45	3.61	7.17	-0.96	-8.93
Total Comprehensive Income	37.9%	768	557	628	620	497	500
Earnings Per Share, Basic	39.6%	167.79	120.51	136.38	133.89	108.77	111.28
Earnings Per Share, Diluted	39.6%	167.79	120.51	136.38	133.89	108.77	111.28

Description	(%) Q/Q	Dec-2025	Jun-2025	Dec-2024	Sep-2024	Jun-2024	Mar-2024
Revenue From Operations	7%	645	603	538	589	563	547
Other Income	-43.9%	38	67	43	43	42	75
Total Income	1.9%	683	670	581	632	605	622
Cost of Materials	-23.9%	68	89	67	77	58	89
Purchases of stock-in-trade	17.1%	145	124	105	81	188	94
Employee Expense	4.2%	100	96	96	101	91	75
Finance costs	-56%	1.99	3.25	1.51	2.1	2.11	6.95
Depreciation and Amortization	0%	14	14	15	15	15	14
Other expenses	7.1%	92	86	99	88	93	93
Total Expenses	5.4%	433	411	408	416	402	378
Profit Before exceptional items and Tax	-3.9%	250	260	172	215	203	244
Exceptional items before tax	-	-58.2	0	0	0	0	0
Total profit before tax	-26.3%	192	260	172	215	203	244
Current tax	-13.6%	58	67	50	60	55	49
Deferred tax	-1357.4%	-7.89	0.39	-5.26	-3.01	-3.14	16
Total tax	-26.9%	50	68	45	57	52	65
Total profit (loss) for period	-26.2%	142	192	128	158	151	179
Other comp. income net of taxes	145.3%	1.87	-0.92	-0.54	-0.53	-0.54	7.93
Total Comprehensive Income	-24.7%	144	191	127	158	150	187
Earnings Per Share, Basic	-26.6%	31.01	41.91	27.89	34.61	32.94	22.33
Earnings Per Share, Diluted	-26.6%	31.01	41.91	27.89	0	32.94	22.33

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	-58.7%	205	495	35	112	16	37
Loans, current	-	0	0	0	0	0	0
Total current financial assets	-1.6%	2,950	2,998	2,531	2,247	2,082	2,076
Inventories	5.1%	500	476	455	434	399	418
Total current assets	-1%	3,477	3,513	3,023	2,738	2,518	2,493
Property, plant and equipment	-9.9%	155	172	132	151	164	178
Capital work-in-progress	-2.1%	7.5	7.64	2.82	0.4	9.38	7.93
Investment property	-	0	0	0	0	0	0
Goodwill	0%	527	527	527	527	527	527
Loans, non-current	-	0	0	0	0	0	0
Total non-current financial assets	0%	14	14	12	14	13	13
Total non-current assets	-19.3%	1,129	1,398	1,404	1,459	1,457	1,476
Total assets	-6.2%	4,606	4,911	4,459	4,229	4,006	4,001
Total non-current financial liabilities	-31.3%	47	68	38	0	73	93
Provisions, non-current	14.3%	65	57	65	0	46	43
Total non-current liabilities	-9.8%	112	124	103	87	119	136
Borrowings, current	0%	2.5	2.5	2.5	2.5	2.5	2.5
Total current financial liabilities	36.8%	317	232	281	206	323	322
Provisions, current	-10%	46	51	57	45	93	101
Current tax liabilities	16.4%	257	221	182	160	164	161
Total current liabilities	13.4%	646	570	605	547	614	657
Total liabilities	9.1%	757	694	708	633	733	793
Equity share capital	0%	46	46	46	46	46	46
Total equity	-8.8%	3,848	4,217	3,751	3,596	3,273	3,207
Total equity and liabilities	-6.2%	4,606	4,911	4,459	4,229	4,006	4,001

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	-47.1%	8.41	15	0	10	-	-
Change in inventories	-154.2%	-42.22	-16	22	-13.86	-	-
Depreciation	-1.6%	61	62	106	115	-	-
Unrealised forex losses/gains	40.2%	0.21	-0.32	0	0	-	-
Adjustments for interest income	-100.6%	0	172	85	49	-	-
Share-based payments	0%	14	14	13	12	-	-
Net Cashflows from Operations	137.1%	973	411	854	893	-	-
Interest received	-	-157.27	0	0	0	-	-
Income taxes paid (refund)	1.3%	156	154	303	226	-	-
Other inflows (outflows) of cash	-	0	0	-195.31	0	-	-
Net Cashflows From Operating Activities	157.4%	660	257	356	667	-	-
Proceeds from sales of PPE	18.4%	0.2	0.02	1.22	2.06	-	-
Purchase of property, plant and equipment	50%	28	19	65	15	-	-
Proceeds from sales of long-term assets	190.4%	152	53	0	0	-	-
Interest received	7.8%	139	129	71	44	-	-
Other inflows (outflows) of cash	-204.7%	-334.43	-109.1	-43.4	-605.54	-	-
Net Cashflows From Investing Activities	-236.5%	-71.34	54	-36.05	-575.02	-	-
Payments of lease liabilities	10%	45	41	35	0	-	-
Dividends paid	-12.6%	160	183	297	160	-	-
Interest paid	-107%	0.3	11	13	0.78	-	-
Other inflows (outflows) of cash	-	0	0	-0.63	-19.99	-	-
Net Cashflows from Financing Activities	12.6%	-205.34	-235.14	-345.79	-180.51	-	-
Net change in cash and cash eq.	416.2%	383	75	-26.14	-88.45	-	-

Industry Group:Pharmaceuticals & Biotechnology

Employees:1,721

Website:www.pfizerltd.co.in

PFIZER - Pfizer Ltd. Share Price

PFIZER

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

PFIZER

PFIZER - Pfizer Ltd. Share Price

PFIZER

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

PFIZER

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Pfizer Ltd. do?

Important Disclosure & Data Context

Valuation

Fundamentals

Profitability

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Pfizer Ltd. do?

Important Disclosure & Data Context